Related references
Note: Only part of the references are listed.Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma
J. Duerinck et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Edwin P. Hui et al.
CLINICAL CANCER RESEARCH (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice
M. Molina-Vega et al.
ENDOCRINE (2018)
The anti-cancer effects of itraconazole in epithelial ovarian cancer
Chel Hun Choi et al.
SCIENTIFIC REPORTS (2017)
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Eun Jin Heo et al.
CANCER RESEARCH AND TREATMENT (2017)
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
Maura Sonego et al.
SCIENTIFIC REPORTS (2017)
Therapeutic targets and new directions for antibodies developed for ovarian cancer
Heather J. Bax et al.
MABS (2016)
Axitinib Affects Cell Viability and Migration of a Primary Foetal Lung Adenocarcinoma Culture
Cecilia Menna et al.
CANCER INVESTIGATION (2014)
Axitinib for the treatment of advanced renal cell carcinoma
Hideyuki Akaza et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
Gerasimos Aravantinos et al.
JOURNAL OF OVARIAN RESEARCH (2014)
miRNA-34b Inhibits Prostate Cancer through Demethylation, Active Chromatin Modifications, and AKT Pathways
Shahana Majid et al.
CLINICAL CANCER RESEARCH (2013)
Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
Marine Gross-Goupil et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2013)
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
Samar Masoumi Moghaddam et al.
CANCER AND METASTASIS REVIEWS (2012)
Expression of 67-kDa laminin receptor was associated with tumor progression and poor prognosis in epithelial ovarian cancer
Taejong Song et al.
GYNECOLOGIC ONCOLOGY (2012)
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
Lubomir Bodnar et al.
GYNECOLOGIC ONCOLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The role of the tissue microenvironment in the regulation of cancer cell motility and invasion
Jan Brabek et al.
CELL COMMUNICATION AND SIGNALING (2010)
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis
Marion Zillhardt et al.
NEOPLASIA (2010)
Improved survival time: What can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?
Lan Huang et al.
CANCER (2008)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer
Lukas A. Hefler et al.
GYNECOLOGIC ONCOLOGY (2006)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Share Paper
